A meta-analysis seeks to determine if adding hormone therapy to radiotherapy after prostatectomy improves overall survival.

Among men with PSA persistence after radical prostatectomy, a higher preoperative PSA surprisingly was linked to lower mortality. Men with PSA persistence and preoperative PSA >20 ng/mL had 31% lower ...

A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.

Epigenomic profiling of circulating chromatin for early detection and monitoring of neuroendocrine prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium.

Real-world treatment patterns and outcomes of novel androgen receptor axis-targeted agents in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study. This is an ...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, a developer of multimodal AI-based prognostic and predictive cancer tests, today announced the commercial launch of the ArteraAI Prostate Test (Post‑RP) for ...

SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...